Search Results for “Johnson ” – Page 29 – media

Onitor Track – A Weight Loss Wearable

Onitor Track is an advanced biometric, data-driven program which aids in weight loss. Onitor Track combines a personalized weight loss and nutrition program with a dual-positioned wearable via an app.
- Source: mHealthSpot
- 2,021
- July 6, 2018
mHealth New Approvals weight loss
Dementia Discovery Fund, Surpassed Funding Target

The DDF initially aimed to raise £130 million with committed investments from GlaxoSmithKline, Biogen, Eli Lilly, Pfizer and Takeda, Johnson & Johnson, as well as the U.K. government’s Department of Health and the nonprofit Alzheimer’s Research UK.
- Source: FierceBiotech
- 609
- June 27, 2018
Company Insight Dementia funding
FDA Seeks Help From Social Media Giants To Help Stop Illegal Opioid Distribution

Scott Gottlieb, FDA Commissioner is looking for help from Facebook and Twitter to slow down the unauthorized opioid sales in the US. Gottlieb invited the two social media giants, among others, to participate in the FDA Online Opioid Summit which is set for June 27.
- Source: Fierce Pharma
- 573
- June 11, 2018
Company Insight digital health FDA opioid
Israel Based Startup Raised $30 Million to Advance AI Devices For Radiologist

The startup also revealed its new research on Textray, which the company claims to be the “most comprehensive Artificial Intelligent research till now.” This is all working towards developing their new product which is currently capable of identifying 40 clinical findings as a result of training via 2 million images.
- Source: TechCrunch
- 862
- June 8, 2018
AI Company Insights x-ray
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 764
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer
Rise in China’s Global Pharma Market up to $175 billion by 2022 – Market Prediction

Though the US stands first in the race in terms of sales and growth, it is highly believed that China would reach the peak in the pharma market by 2022. At present, since there has been a decrease in public health funding, there has been a slight fall in pharmerging countries like Brazil, Russia, India and China (BRIC). But it is believed that the condition of these pharmerging countries will improve in the next five years [1].
- Source: Ddu
- 822
- May 24, 2018
China Market Views pharmaceutical drugs
AbbVie pressurized to keep low price for Imbruvica formula

This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
- Source: Ddu
- 1,109
- May 17, 2018
AbbVie Company Insight pharma pharmaceutical
Breakdown of Pharma Events Since 2017

As a new, erratic administration consolidated its position in the White House and firmed its foundations in the federal government, 2017 turned out to be uncertain for the biopharma industry. Then President-elect Donald Trump saying that the industry was getting away with murder on pricing did not bode well for the industry but more than a year later after the President assuming office, real reform has been spared for biopharma.
- Source: Ddu
- 655
- May 17, 2018
global pharma influencers Market Views pharma
FDA approved Pfizer biosimilar Epogen/Procrits

The FDA granted approval to Pfizer for Retacrit (epoetin alfa-epbx), which is used for the treatment of anemia, biosimilar of Amgen, a drug which generated sales closely $ 1.8 billion in the U.S market last year for Amgen and Johnson & Johnson partners. Retacrit also received the go-ahead to be used in RBC transfusions by U.S health regulators.
- Source: Ddu
- 684
- May 16, 2018
anemia New Approvals Pfizer pharma
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities
- Source: janssen
- 581
- May 3, 2018
acquisition Janssen oncolytic immunotherapies

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.